semaglutide and epilepsy Tied to 50% Lower Risk for in Diabetes GLP-1 Diabetes Medications Linked to

Sherr, S

For PD, the aim is to protect dopaminergic neurons, improve mitochondrial function, reduce -synuclein accumulation and formulate gene therapies

The goal is to feel less like eating, not too sick to eat

These drugs have changed the entire treatment perspective for type 2 diabetes and obesity, and in recent years, GLP-1 receptor agonists have also been shown to protect the heart and kidneys, explains Jens Juul Holst

Gimsing P, Hippe E

To assess the association of semaglutide with incident CUD, the study population included 587,849 patients with T2D who had active medical encounters for T2D during 12/20175/2021, were for the first time prescribed semaglutide (Ozempic) or non-GLP1-1RA anti-diabetes medications (new-user design) during 12/20175/2021(index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event